Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05473507 · ClinicalTrials.gov registry record
A Study of Observation and Follow-up in People With Basal Cell Carcinoma
A clinical trial of Basal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 26
- Enrollment target
- 1
- Study location
NCT05473507: Active study of Basal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05473507 is a study of Basal Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 26 participants, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05473507, a study of Basal Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out more about how Basal Cell Carcimonas/BCCs grow and to learn more effective ways to monitor and treat these common cancers. This study will not provide any type of treatment for the participants' cancer; it is a 3-year observational study to monitor participants' cancer.
Primary Outcome
To adequately measure the growth dynamics of tumors, several imaging modalities will be employed. Longest dimension (millimeters) of the lesion from clinical imaging will be the primary measurement of horizontal extent of the lesion. Maximum lesion depth (millimeters) from OCT imaging will be the primary measured of vertical extension.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Optical coherence tomography (OCT)
- DIAGNOSTIC_TEST Digital Dermoscopy
- DIAGNOSTIC_TEST Reflectance confocal microscopy (RCM)
- DIAGNOSTIC_TEST Dermtech tape-stripping
- DIAGNOSTIC_TEST Total Skin Examinations
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2026-07 |
What the registry record for NCT05473507 still lists
NCT05473507 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Optical coherence tomography (OCT) is the first listed.
NCT05473507 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05473507 about?
NCT05473507 is a clinical study titled "A Study of Observation and Follow-up in People With Basal Cell Carcinoma". The purpose of this study is to find out more about how Basal Cell Carcimonas/BCCs grow and to learn more effective ways to monitor and treat these common cancers. This study will not provide any type of treatment for the participants' cancer; it is a 3-year observational study to monitor participan...
What is the current status of trial NCT05473507?
This trial is currently active not recruiting. The enrollment target is 26 participants. The study started on 2022-07-27. Estimated completion is 2026-07.
What conditions does trial NCT05473507 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT05473507?
The interventions under investigation include: Optical coherence tomography (OCT) (DIAGNOSTIC_TEST), Digital Dermoscopy (DIAGNOSTIC_TEST), Reflectance confocal microscopy (RCM) (DIAGNOSTIC_TEST), Dermtech tape-stripping (DIAGNOSTIC_TEST), Total Skin Examinations (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05473507?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05473507 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05473507's enrollment target sits among peer trials
26 22nd of 24 higher than 3 of 24 other Basal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Basal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI